Last edition
News about "Geoffrey Ku"
US FDA Approves Ziihera for First-Line HER2+ Gastroesophageal Cancer
The US Food and Drug Administration (FDA) approves Ziihera plus tislelizumab and chemotherapy for first-line treatment of HER2+ advanced gastroesophageal adenocarcinoma regardless of PD-L1 status.
Geoffrey Ku | 26/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members